MIDTERM RESULTS OF THE OBSERVATIONAL NON-INTERVENTIONAL CLINICAL STUDY "EVALUATION OF THE EFFECTIVENESS OF THE CARNITINE OROTATE AND BIPHENYLDIMETHYLDICARBOXYLATE COMPLEX IN THE PATHOGENETIC THERAPY OF METABOLIC-ASSOCIATED FATTY LIVER DISEASE: A PROSPEC
Introduction. Metabolic dysfunction-associated fatty liver disease (MAFLD) is a widespread pathology requiring effective treatment approaches. One promising direction is the use of a complex of carnitine orotate and biphenyldimethyldicarboxylate (COC and BDD), which possess antioxidant and hepatoprotective properties.
Materials and methods. As part of the observational, non-interventional, prospective cohort study KASVM-01 [NCT06078722], the impact of COC and BDD on the progression of MAFLD in patients in the Republic of Kazakhstan was investigated. From February 2023 to July 2024, a total of 121 participants from Almaty and Almaty Region were enrolled in the study and received COC and BDD. The observation period lasted 12 months, with an interim analysis conducted on 78 participants who completed a 24-week treatment course. Anthropometric parameters (BMI, waist circumference), liver steatosis and fibrosis levels measured via transient elastography (FibroScan) with CAP, ALT, AST, total cholesterol, triglycerides, and FIB-4 (a non-invasive fibrosis marker) were assessed at baseline and after completing 24 weeks of therapy with COC and BDD.
Results. The interim analysis revealed a statistically significant reduction in ALT levels (from 32.4 to 20.1 U/mL, p<0.001), triglycerides (from 1.4 to 1.3 mmol/L, p=0.007), steatosis grade (from 304 to 283 dB/m, p<0.001), and fibrosis level (from 6.5 to 6.0 kPa, p=0.022). The prevalence of severe steatosis (S3) decreased from 52.7% to 45.7%, whereas mild steatosis (S1, S0) increased to 21.4% and 10%, respectively (p=0.001). The proportion of patients with F3 fibrosis declined from 8.1% to 1.4%, while F2 fibrosis decreased from 27% to 21.4% (p=0.022), indicating an improvement in fibrosis markers. During the observation period, BMI decreased (from 30.4 to 29.8 kg/m²), although the changes were not statistically significant (p=0.214). No significant changes were observed in total cholesterol and FIB-4 levels.
Conclusion. The interim analysis confirmed the effectiveness of COC and BDD in the treatment of MAFLD, demonstrating improvements in biochemical parameters as well as regression of liver steatosis and fibrosis. Further research and validation of these findings in later stages of observation are necessary to assess the final efficacy and long-term safety of the therapy.
Количество просмотров: 604
Категория статей:
Oригинальное исследование
Библиографическая ссылка
Jumabayeva A., Kaibullayeva J., Kaisina A., Nugmanova B., Zhumadilova Z., Botabayeva A., Ualiyeva A., Pashimov M., Kambarova G., Omarova K., Muratbekova A., Balabek A., Yergaliyeva A., Reshidova T., Saktagan A., Kassymova T., Mutaliyeva G., Anuar A., Kudaibergenova Sh. Midterm results of the observational non-interventional clinical study "Evaluation of the effectiveness of the carnitine orotate and biphenyldimethyldicarboxylate complex in the pathogenetic therapy of metabolic-associated fatty liver disease: a prospective cohort study» // Nauka i Zdravookhranenie [Science & Healthcare]. 2025. Vol.27 (1), pp. 7-14. doi 10.34689/SH.2025.27.1.001Похожие публикации:
MIDTERM RESULTS OF THE OBSERVATIONAL NON-INTERVENTIONAL CLINICAL STUDY "EVALUATION OF THE EFFECTIVENESS OF THE CARNITINE OROTATE AND BIPHENYLDIMETHYLDICARBOXYLATE COMPLEX IN THE PATHOGENETIC THERAPY OF METABOLIC-ASSOCIATED FATTY LIVER DISEASE: A PROSPEC
GENETIC ANALYSIS OF TP53 AND CTNNB1 MUTATIONS IN PEDIATRIC MEDULLOBLASTOMA: A STUDY FROM KAZAKHSTAN
ЭПИЛЕПСИЯЛЫҚ БЕЛСЕНДІЛІК КЕЗІНДЕ ПАРОКСИЗМАЛЬДЫ ДЕПОЛЯРИЗАЦИЯЛЫҚ ЫҒЫСУ КЛАСТЕРЛЕРІНІҢ ҚҰРЫЛЫМЫНА Kv7 ТҰҚЫМДАС КАЛИЙ КАНАЛДАРЫНЫНЫҢ ИНГИБИТОРЛАРЫ МЕН АКТИВАТОРЛАРЫНЫҢ ӘСЕРІН ЗЕРТТЕУ
ЧАСТОТА РЕЦИДИВОВ ГАСТРОЭЗОФАГЕАЛЬНОЙ РЕФЛЮКСНОЙ БОЛЕЗНИ У ДЕТЕЙ ШКОЛЬНОГО ВОЗРАСТА
УРОВЕНЬ ЗАБОЛЕВАЕМОСТИ САХАРНЫМ ДИАБЕТОМ 2 ТИПА И ХРОНИЧЕСКИМ ВИРУСНЫМ ГЕПАТИТОМ С НА 2023 ГОД В ГОРОДЕ АЛМАТЫ